BIRC5 and cancer: Summarily, there are five main categories of targeted survivin cancer therapeutics in the current: survivin immunotherapy, survivin mRNA inhibitors, survivin transcription inhibitors, survivin homodimerization and survivin-partner protein interaction inhibitors 51-53.